Henry C Fung, Chair and Professor, Department of Bone Marrow Transplant and Cellular Therapy at Fox Chase Cancer Center, shared a post on X:
“MajesTEC-4 was the most fascinating study reported at EHA 2026 for me.
Not because 100% MRD negativity (10⁻⁵) was achieved. What truly caught my attention was the magnitude and speed of CR/sCR conversion.
After ASCT, CR/sCR rates were approximately 25-40%. Within 6-12 months of Tec-based maintenance, CR/sCR approached 100%. That is breathtaking. MASTER, CASSIOPEIA, and PERSEUS established an extraordinarily high bar.
MajesTEC-4 is now challenging those landmark studies despite being an early run-in cohort of ~90 patients. The deeper question is not whether teclistamab is active. We already know it is. The question is why it appears so active in the post-ASCT setting. Where do the effector T cells come from?
Are they predominantly reinfused with the autograft?
Do the classic Mayo observations linking early lymphocyte recovery to superior outcomes offer a clue?
Perhaps ASCT is doing more than cytoreduction. Perhaps maintenance is doing more than maintaining. Step by step. Trial by trial. Not only are responses becoming deeper. More patients are achieving them, and they are achieving them faster.”
Other articles featuring Henry C Fung on OncoDaily.